- Details
- In this presentation, Susan Halabi discusses the implications of subgroup analyses in metastatic castration-resistant prostate cancer (mCRPC) trials during the management of CRPC session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The challenge, according to Dr. Halabi, is balancing the dichotomy of the danger of interpreting subgroup analysis with applying overall results o...
|
- Details
- Mary-Ellen Taplin presents on the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel or AR pathway inhibitors in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. There are currently no prospective clinical trial data to guide the optimal selection of treatment for first-line mCRPC after ADT/docetaxel or ADT/AR-inhibition. Dr. Taplin exp...
|
- Details
- Maha Hussain presents during the Management of Castration-Resistant Prostate Cancer (CRPC) debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Hussain focuses on the "pros" of treating men with non-metastatic CRPC while revisiting the transformation of the field back to 2011 where stood an area of unmet need. The past 18 months have seen the reporting and FDA approval of...
|
- Details
- Celestia (Tia) Higano followed Maha Hussain's presentation on the "pros" of the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with the opposing side of the debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Higano focuses on the "cons" of treating men with nmCRPC and highlights an extensively covered topic at the meeting, the emergence and upd...
|
- Details
- At the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Alberto Briganti shares his thoughts on where he would like to see the treatment of locally advanced prostate cancer in the future. Dr. Briganti's presentation covers 4 major areas where he views opportunity for progress: the intensification of tailored multi-modal approaches, image-guided surgery, the use of novel tools to improve...
|
- Details
- Oliver Sartor presented the impact and use of radium-223 during the Bone and Bone Metastases Session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Sartor explains how Radium-223 first gained prominence with the reporting of the ALSYMPCA trial in 2013 which led to the FDA approval of radium-223 in the United States for patients with bone mCRPC without visceral metastases hi...
|
- Details
- Matthew Smith presented a summary detailing the best use of osteoclast-targeted therapy for patients with bone metastatic castration-resistant prostate cancer (mCRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Emphasizing the importance to distinguish between skeletal-related events and fragility fractures secondary to osteoporosis, Dr. Smith covers the current landscape fo...
|
- Details
- (Length of Interview: 14 min) John Fortin interviews Art Rastinehad on a new publication published in the Proceedings of the National Academy of Science on prostate cancer and nanomedicine. Art Rastinehad and colleagues at Icahn Scool of Medicine at Mount Sinai are the first to perform human trials using nanoshell directed photothermal ablation. In this podcast interview, Dr. Rastinehad reports th...
|
- Details
- Robin Millman, a patient advocate, and 20+ year prostate cancer survivor shares a patient's perspective on the treatment landscape journey and hopes for the future of advanced prostate cancer treatment at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. He highlights areas of interest and opportunity including general population screening and improved utilization of active surveilla...
|
- Details
- Charles Ryan presented the management of fatigue and cognitive changes induced by androgen deprivation therapy (ADT) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Ryan discusses the association between ADT and dementia, and also how combining ADT with abiraterone and prednisone can significantly improve fatigue in patients. Biographies: Charles J. Ryan, MD , the President...
|